Bahareh Marghoob
1* 
, Mohammad Hassan Fallahkohan
2 1 Iran University of Medical Sciences, Hasheminejad Kidney Center, School of Medicine, Nephrology Department, Tehran, Iran
2 Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract
Systemic amyloidosis is a collection of diseases caused by the deposition of protein fibrils in organ tissues, leading to significant morbidity. Cardiac amyloidosis, a rare and debilitating condition, can affect any organ in the body. The two primary types of cardiac amyloidosis are systemic light chain (AL) amyloidosis, which is more common and related to light chain overproduction in the bone marrow, and wild-type transthyretin cardiac amyloidosis (ATTRwt). This case report describes a unique and uncommon case of cardiac amyloidosis observed in a patient following kidney transplant, which was effectively managed using a novel therapeutic regimen.
Implication for health policy/practice/research/medical education:
This case report describes a cardiac AL amyloidosis observed in a kidney transplant patient, which was diagnosed and effectively managed with a daratumumab-based chemotherapy regimen (Dara-CyBorD), supporting the current literature.
Please cite this paper as: Marghoob B, Fallahkohan MH. Cardiac amyloidosis in a kidney transplant recipient. J Nephropathol. 2025;14(4):e27610. DOI: 10.34172/jnp.2025.27610.